| Gene Symbol | KARS1 |
|---|
| Full Name | Lysyl-tRNA Synthetase 1 |
|---|
| Chromosomal Location | 16q23.3 |
|---|
| NCBI Gene ID | [5751](https://www.ncbi.nlm.nih.gov/gene/5751) |
|---|
| OMIM | [614421](https://www.omim.org/entry/614421) |
|---|
| Ensembl ID | [ENSG00000013375](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000013375) |
|---|
| UniProt | [Q15020](https://www.uniprot.org/uniprotkb/Q15020/entry) |
|---|
| Associated Diseases | Charcot-Marie-Tooth disease (CMT) type 2, recessive intermediate neuropathy, mitochondrial disease, hereditary spastic paraplegia, auditory neuropathy |
|---|
KARS1 (Lysyl-tRNA Synthetase 1) encodes a crucial enzyme for protein synthesis, catalyzing the attachment of lysine to its cognate tRNA molecule during translation 1. This essential function makes KARS1 indispensable for cellular viability across all organisms. However, emerging research has revealed that KARS1, like other aminoacyl-tRNA synthetases (aaRS), possesses diverse extra-translational functions that extend far beyond its canonical role in protein synthesis 2.
Mutations in KARS1 have been implicated in several human diseases, particularly peripheral neuropathies and mitochondrial disorders, highlighting the critical importance of this enzyme in neuronal health and function 3. The dual functionality of KARS1—serving both as a translation factor and as a signaling molecule—makes it a fascinating target for understanding neurodegenerative disease mechanisms and developing therapeutic interventions.
¶ Molecular Structure and Function
KARS1 is a ~622 amino acid protein with a characteristic bilobal structure typical of class II aminoacyl-tRNA synthetases:
-
N-terminal Domain: Contains the catalytic core that binds ATP and amino acid, catalyzing the first step of the aminoacylation reaction.
-
C-terminal Domain: Responsible for tRNA recognition and binding, ensuring correct pairing between amino acid and tRNA isoacceptor.
-
Editing Domain: Prevents mischarging of tRNA with incorrect amino acids, maintaining translational fidelity.
The protein exists as both a cytoplasmic form and, through alternative splicing, a mitochondrial form (KARS2 or mtKARS), enabling proper translation in both cellular compartments 4.
The aminoacylation reaction proceeds through two-step chemistry:
Step 1: Activation
Lysine + ATP → Lysyl-AMP + PPi
Step 2: Transfer
Lysyl-AMP + tRNA^Lys → Lysyl-tRNA^Lys + AMP
The overall reaction is highly accurate, with error rates less than 1 in 10,000, critical for proper protein synthesis.
Beyond translation, KARS1 participates in several non-canonical functions:
-
RNA Splicing: In the nucleus, KARS1 contributes to RNA splicing through interactions with splicing factors.
-
Cell Signaling: KARS1 can be secreted and function as a cytokine-like signaling molecule, activating immune responses.
-
Immune Modulation: Extracellular KARS1 binds to receptors on immune cells, modulating inflammatory responses.
-
DNA Repair: Some evidence suggests roles in DNA damage response pathways.
KARS1 mutations are a well-established cause of Charcot-Marie-Tooth disease (CMT), a hereditary peripheral neuropathy characterized by progressive muscle weakness and sensory loss:
| Type |
Inheritance |
Phenotype |
Mechanism |
| CMT2 |
Autosomal recessive |
Intermediate neuropathy |
Loss of function |
| CMT-DID |
Autosomal recessive |
Developmental delay, neuropathy |
Compound heterozygous |
| CMT-R |
Autosomal recessive |
Classical CMT phenotype |
Biallelic variants |
The peripheral neuropathy in CMT patients with KARS1 mutations likely results from impaired protein synthesis in axons and Schwann cells, affecting nerve maintenance and regeneration 5.
KARS1 variants affecting the mitochondrial-targeted isoform cause mitochondrial translation defects:
- Combined Oxidative Phosphorylation Deficiency: Impaired mitochondrial protein synthesis
- Encephalomyopathy: Progressive encephalopathy with muscle involvement
- Sensorineural Hearing Loss: Mitochondrial dysfunction in inner ear
These phenotypes underscore the importance of mitochondrial translation for energy metabolism in high-energy tissues like neurons and muscle 6.
Specific KARS1 mutations cause pure hereditary spastic paraplegia, characterized by progressive lower limb spasticity and weakness due to upper motor neuron degeneration. This suggests that KARS1 dysfunction particularly affects long corticospinal tract axons 7.
KARS1 mutations have been identified in patients with auditory neuropathy, a hearing disorder characterized by preserved outer hair cell function but impaired neural transmission. This reflects the unique vulnerability of the auditory nerve to translational defects.
Some KARS1 variants are associated with intellectual disability, developmental delay, and neurological symptoms including:
- Microcephaly
- Ataxia
- Seizures
- Brain malformations
These phenotypes suggest critical roles for KARS1 in neuronal development and function 8.
Neurons are particularly dependent on robust protein synthesis for:
-
Axonal Maintenance: Axons require continuous protein synthesis for cytoskeletal maintenance, organelle trafficking, and membrane remodeling.
-
Synaptic Plasticity: Synapses undergo continuous protein turnover for receptor trafficking, scaffolding protein replacement, and local translation during long-term potentiation.
-
Myelin Maintenance: Both central and peripheral myelin require ongoing protein synthesis for maintenance and repair.
KARS1 dysfunction impairs these processes, leading to progressive neuronal dysfunction.
The mitochondrial isoform of KARS1 is essential for translating mitochondrial-encoded proteins:
- Complex I Deficiency: Reduced assembly of NADH dehydrogenase complex
- ATP Production: Impaired oxidative phosphorylation
- Reactive Oxygen Species: Increased ROS production and oxidative stress
Neurons, with their high energy demands and mitochondrial density, are particularly vulnerable to these defects 9.
KARS1 mutations may affect axonal transport through:
- Impaired synthesis of transport proteins
- Mitochondrial dysfunction affecting energy supply
- Direct effects on cytoskeletal proteins
KARS1 dysfunction triggers ER stress through multiple mechanisms:
- Unfolded Protein Response: Accumulation of misfolded proteins in the ER due to translation fidelity issues activates the UPR
- ER Calcium Depletion: Disrupted calcium homeostasis affects protein folding capacity
- CHOP Expression: Pro-apoptotic signaling through C/EBP homologous protein
- Global Translation Repression: Integrated stress response reduces overall protein synthesis
Neuronal vulnerability to oxidative stress is exacerbated by KARS1 deficiency:
- Mitochondrial ROS overproduction: Complex I dysfunction leads to increased superoxide
- Impaired antioxidant defenses: Reduced synthesis of antioxidant enzymes
- Lipid peroxidation: Membrane damage from reactive oxygen species
- DNA damage accumulation: 8-oxoguanine lesions in nuclear and mitochondrial DNA
While primarily known for peripheral neuropathies, KARS1 dysfunction contributes to AD pathogenesis through multiple mechanisms 18:
Protein Synthesis Decline:
- Global reduction in translation capacity with aging
- Impaired local protein synthesis at synapses critical for LTP
- Reduced capacity for activity-dependent protein synthesis
- Deficit in long-term potentiation maintenance
Synaptic Dysfunction:
- Reduced AMPA and NMDA receptor subunit synthesis
- Impaired scaffolding protein (PSD-95, Homer) production
- Disrupted activity-dependent translation at dendritic spines
- Loss of synaptic connectivity and spine density
Connection to Amyloid Pathology:
- Altered APP processing due to translation defects in secretases
- Effects on BACE1 and γ-secretase component expression
- Potential for increased Aβ production
- Impaired Aβ clearance mechanisms
Tau Pathology Connection:
- Altered translation of MAPT (tau) isoforms
- Effects on tau phosphorylation via dysregulated kinases
- Potential for aggregation-prone species accumulation
- Impaired tau clearance through autophagy
Mitochondrial Dysfunction:
- Reduced mitochondrial protein synthesis
- Impaired complex I and IV assembly
- Energy failure in highly metabolic neurons
- Increased oxidative stress and ROS production
KARS1 function intersects with PD pathogenesis through several pathways 19:
tRNA Modifications and Translation Fidelity:
- Post-transcriptional tRNA modifications (e.g., queuosine, wybutosine) affect translation fidelity
- Altered tRNA modification patterns in PD substantia nigra
- Implications for α-synuclein (SNCA) protein synthesis
- Error-prone translation leads to protein misfolding and aggregation
Mitochondrial Translation in Dopaminergic Neurons:
- Complex I defects in PD substantia nigra are well-documented
- Critical role of mitochondrial translation in dopaminergic neuron survival
- Energy failure mechanisms underlying neuronal vulnerability
- Particular sensitivity of dopaminergic neurons to translation defects
Axonal Transport and Local Translation:
- Local translation in dopaminergic axons is essential for axonal maintenance
- Axonal protein synthesis requirements in long neuronal projections
- Vulnerability to translation defects in distal axon segments
- Impaired axonal regeneration following injury
Alpha-Synuclein Connection:
- Direct translation of SNCA protein at ribosomes
- Effects of misfolded proteins on translation machinery
- Potential for aggregation seeding due to translation errors
- Autophagy-lysosomal pathway dysfunction from protein overload
Neuroinflammation:
- Microglial activation in response to neuronal dysfunction
- Cytokine release affecting neuronal survival
- Chronic neuroinflammation progression
- Feedback loop between neuronal dysfunction and immune response
Understanding KARS1's role in neurodegeneration suggests several therapeutic approaches:
- Gene Therapy: Restoring proper KARS1 expression
- Aminoacyl-tRNA Synthetase Boosters: Enhancing residual enzyme activity
- Mitochondrial Protectors: Supporting mitochondrial function
- Neuroprotective Agents: Enhancing neuronal survival mechanisms
KARS1 is expressed ubiquitously, with highest levels in:
- Brain: Cerebral cortex, hippocampus, cerebellum
- Spinal Cord: Motor neurons
- Peripheral Nerves: Schwann cells, dorsal root ganglia
- Heart: Cardiac muscle
- Skeletal Muscle: Skeletal myocytes
- Liver: Hepatocytes
- Kidney: Tubular cells
- Cytoplasm: Main pool for cytoplasmic translation
- Mitochondria: Mitochondrial-targeted isoform
- Nucleus: Some nuclear localization for splicing functions
- Secreted: Can be released extracellularly under certain conditions
KARS1 expression is highest during development, consistent with the high protein synthesis demands of growing neurons and developing tissues.
KARS1 interacts with several proteins:
- Other aaRS: Forms multisynthetase complex
- EF-1α: Translation elongation factor
- AIMP1: Aminoacyl-tRNA synthetase-interacting protein
- tRNA Processing Proteins: Splicing and maturation factors
- MTOR Pathway: Links nutrient sensing to translation
- Integrated Stress Response: Global translation control
- Mitochondrial Dynamics: Quality control and biogenesis
-
Enzyme Replacement: While challenging for large proteins, AAV-mediated gene delivery could restore KARS1 function.
-
Small Molecule Modulators: Compounds that enhance residual KARS1 activity or stability.
-
Mitochondrial Support: CoQ10, L-carnitine, and other mitochondrial supplements.
-
Neuroprotective Strategies: Supporting axonal integrity and synaptic function.
- Blood-Brain Barrier: CNS delivery remains challenging
- Tissue Specificity: Peripheral vs. CNS manifestations
- Dosage Effects: Balancing function across tissues
- Mutation Characterization: Understanding how specific variants affect function
- Mechanism Studies: Defining pathogenic mechanisms in neurons
- Model Systems: iPSC-derived neurons and animal models
- Therapeutic Screening: Identifying candidate compounds
- Gene Editing: CRISPR-based approaches for precise correction
- Protein Engineering: Enhanced enzyme variants
- Biomarkers: Disease progression markers
- Aminoacyl-tRNA synthetases in human disease - 2017
- Human mitochondrial aminoacyl-tRNA synthetases - 2017
- KARS1 mutations cause hereditary spastic paraplegia - 2015
- Mitochondrial KARS and translation - 2011
- CMT2 and KARS1 mutations - 2018
- Mitochondrial translation defects in disease - 2015
- HSP with KARS1 mutation - 2015
- Neurodevelopmental disorders with aaRS mutations - 2020
- Mitochondrial dysfunction in neurodegeneration - 2014
- KARS1 and CMT disease severity - 2020
- Aminoacyl-tRNA synthetase complex - 2015
- Cytosolic vs mitochondrial KARS isoforms - 2011
- KARS1 missense variants in neuropathy - 2018
- tRNA charging in neuronal health - 2020
- KARS1 and axonal transport - 2019
- Mitochondrial translation machinery - 2014
- Neuropathy gene panels and KARS1 - 2017
- aaRS therapies and drug discovery - 2020
- KARS1 structural analysis - 2015
- KARS1 in auditory neuropathy - 2017
¶ Translation Fidelity and Quality Control
The accuracy of tRNA charging by KARS1 is critical for proper protein synthesis:
Error Prevention Mechanisms:
- Pre-transfer Editing: The editing domain hydrolyzes misactivated amino acids before tRNA transfer
- Post-transfer Editing: Removes incorrectly charged amino acids from tRNA
- Kinetic Proofreading: Active site discrimination through rate differences
Translational fidelity rates exceed 99.99%, with errors occurring less than once per 10,000 codons translated. This precision is essential for neurons, where misfolded proteins can aggregate and trigger stress responses 10.
KARS1 is part of a larger multisynthetase complex (MSC) that coordinates translation:
Complex Components:
- AIMP1/p43: Scaffolding protein that stabilizes the complex
- AIMP2/p38: Tumor suppressor, regulates cell death
- Other aaRS: EPRS, LARS, IARS, MARS, QARS, RARS, KARS
This complex enables efficient tRNA delivery to ribosomes and may have regulatory functions beyond translation 11.
KARS1 produces multiple isoforms through alternative splicing 12:
| Isoform |
Localization |
Function |
| KARS1-1 |
Cytoplasm |
Cytoplasmic translation |
| KARS1-2 |
Mitochondria |
Mitochondrial translation |
| KARS1-3 |
Nucleus |
RNA processing |
The mitochondrial isoform (sometimes called KARS2) contains an N-terminal targeting sequence that directs it to the mitochondrial matrix.
KARS1 mutations cause axonal degeneration through multiple pathways:
Primary Mechanisms:
- Impaired Local Translation: Axons require local protein synthesis for maintenance
- Mitochondrial Dysfunction: Energy deficiency in long axons
- Defective Cytoskeletal Assembly: Reduced synthesis of tubulin and actin
- Impaired Transport: Reduced motor protein function
Secondary Consequences:
- Wallerian-like degeneration
- Distal axonopathy
- Retrograde degeneration
- Synaptic dysfunction
KARS1 deficiency affects not only neurons but also supporting glial cells:
Schwann Cell Impact:
- Impaired myelin maintenance
- Decreased myelination capacity
- Demyelination
Astrocyte Impact:
- Reduced support for neuronal metabolism
- Altered glutamate handling
- Increased inflammatory responses
KARS1 dysfunction leads to broader cellular stress:
Unfolded Protein Response (UPR):
- Accumulation of misfolded proteins
- ER stress signaling
- Translational attenuation
Autophagy Dysregulation:
- Reduced autophagy capacity
- Accumulation of damaged organelles
- Impaired aggregate clearance
KARS1 mutations associated with disease include 13:
Mutation Types:
- Missense variants (most common)
- Splice-site mutations
- Nonsense variants (severe phenotype)
- Frameshift insertions/deletions
Hotspot Regions:
- Catalytic domain (residues 100-300)
- Editing domain (residues 300-450)
- C-terminal tRNA-binding domain (residues 500-622)
| Mutation Type |
Phenotype |
Severity |
| Biallelic missense |
CMT2 |
Moderate |
| Compound heterozygous |
CMT-DID |
Moderate-severe |
| Homozygous nonsense |
HSP |
Severe |
| Heterozygous |
Auditor neuropathy |
Mild |
- KARS1 variants have global distribution
- Founder mutations identified in specific populations
- Carrier frequency varies by ethnicity
¶ Diagnostic and Therapeutic Approaches
Diagnostic Pipeline:
- Clinical evaluation (neurological exam)
- Electrophysiology (nerve conduction studies)
- Genetic testing (gene panel or exome)
- Functional validation (if variant of uncertain significance)
Biomarkers:
- Plasma amino acid levels
- Mitochondrial function assays
- Fibroblast studies
Current Approaches 14:
-
Gene Therapy:
- AAV-mediated KARS1 delivery
- Antisense oligonucleotide approaches
- CRISPR-based gene editing
-
Protein-Based Therapy:
- Recombinant KARS1 enzyme replacement
- Aminoacyl-tRNA synthetase boosters
-
Small Molecule Interventions:
- Translational fidelity enhancers
- Mitochondrial protectors
- Neuroprotective agents
-
Supportive Care:
- Physical therapy
- Orthopedic interventions
- Assistive devices
No KARS1-specific clinical trials exist as of 2025, but broader trials include:
- Charcot-Marie-Tooth disease gene therapy trials
- Mitochondrial disease treatment trials
- Peripheral neuropathy therapeutic trials
ZebraFish Models:
- kars morphant phenotype
- Knockout models showing neuropathy
- Drug screening platforms
Mouse Models:
- Conditional knockout in neurons
- Tissue-specific deletion
- Phenotype characterization ongoing
Patient-Derived Models 15:
- iPSC-derived neurons
- Patient fibroblasts
- Engineered cell lines
- Purified protein characterization
- Enzyme kinetics analysis
- Structure-function studies
KARS1 is highly conserved across species:
- Bacteria to humans
- Essential for viability
- Both cytosolic and mitochondrial forms
| Species |
Features |
| C. elegans |
Single KARS, both functions |
| Drosophila |
Separate cytosolic/mitochondrial |
| Zebrafish |
Orthologous functions |
| Mouse |
Highly similar to human |
| Humans |
Alternative splicing complexity |
- Mechanism Elucidation: Define precise pathogenic mechanisms
- Therapeutic Development: Identify drug candidates
- Biomarker Discovery: Develop disease progression markers
- Natural History Studies: Understand disease course
- Single-cell RNA sequencing
- Proteomics approaches
- Advanced imaging techniques
- Organoid models
- International CMT registries
- KARS1 variant databases
- Patient advocacy groups
- Research consortiums
¶ Molecular Interactions and Signaling Networks
KARS1 participates in multiple cellular stress response pathways beyond its canonical translation functions:
Integrated Stress Response (ISR):
The Integrated Stress Response is activated by various cellular stresses including ER stress, mitochondrial dysfunction, and nutrient deprivation. KARS1 plays a role in this pathway through its requirement for global protein synthesis during stress recovery. When cells experience stress, global translation is attenuated through eIF2α phosphorylation, but specific stress-response proteins are still synthesized. KARS1's activity is essential for translating these crucial stress-response proteins, making it a critical component of cellular survival mechanisms.
ER Stress and Unfolded Protein Response:
The ER is particularly sensitive to perturbations in protein folding capacity. KARS1 mutations can contribute to ER stress through:
- Accumulation of mistranslated proteins
- Impaired folding capacity
- Activation of downstream stress signaling
Oxidative Stress Response:
Mitochondrial dysfunction caused by KARS1 deficiency leads to increased reactive oxygen species (ROS). Cells respond through:
- Antioxidant gene activation (Nrf2 pathway)
- Mitochondrial quality control (mitophagy)
- Metabolic adaptation
¶ KARS1 and the Proteostasis Network
The cellular protein homeostasis network coordinates protein synthesis, folding, quality control, and degradation:
Molecular Chaperone Interactions:
KARS1 interacts with several chaperone systems:
- HSP70 family: Assists in protein folding
- HSP90 family: Manages mature protein complexes
- Chaperonin TRiC/CCT: Folds cytoskeletal proteins
Degradation Pathways:
- Ubiquitin-Proteasome System: Degrades misfolded proteins
- Autophagy-Lysosome Pathway: Clears aggregates and damaged organelles
Neurons have unique requirements for KARS1 function:
Local Translation in Axons:
Axons contain specialized translation machinery for local protein synthesis. KARS1 is required for:
- Cytoskeletal maintenance proteins
- Transport proteins (kinesins, dyneins)
- Synaptic protein precursors
- Mitochondrial proteins for local energy production
Synaptic Function:
Synapses require continuous protein turnover for:
- Receptor trafficking and recycling
- Scaffolding protein replacement
- Neurotransmitter release machinery
- Postsynaptic density maintenance
Myelin Maintenance:
Both central and peripheral myelin require ongoing protein synthesis for:
- Myelin basic protein (MBP) production
- Myelin protein zero (MPZ)
- Peripheral myelin protein 22 (PMP22)
Clinical Features:
- Progressive distal weakness
- Sensory loss
- Foot deformities (pes cavus, hammertoes)
- Reduced or absent reflexes
- Variable age of onset
Diagnostic Testing:
- Nerve Conduction Studies: Show axonal neuropathy
- EMG: Denervation patterns
- MRI/Nerve Ultrasound: May show nerve thickening
- Genetic Testing: Confirm pathogenic variants
Multidisciplinary Care:
- Neurology
- Physical/Occupational Therapy
- Orthopedic Surgery
- Pain Management
- Genetic Counseling
Rehabilitation Approaches:
- Strengthening exercises
- Balance training
- Gait optimization
- Assistive devices
Monitoring:
- Disease progression tracking
- Respiratory function (in severe cases)
- Cardiac function (in mitochondrial forms)
- Hearing evaluation
Gene Replacement Therapy:
AAV vectors can deliver functional KARS1 to affected tissues. Challenges include:
- Achieving sufficient expression
- Targeting both CNS and peripheral nervous system
- Avoiding immune response
Small Molecule Approaches:
- Translation fidelity enhancers: Improve accuracy
- Mitochondrial protectants: Support energy metabolism
- Neuroprotective compounds: Enhance neuronal survival
Antisense Oligonucleotides:
- Splice-correcting ASOs
- NMD-blocking ASOs for nonsense variants
¶ Public Health and Research Infrastructure
- CMT affects approximately 1 in 2500 people
- KARS1 accounts for ~1-2% of CMT cases
- Both sporadic and familial cases reported
- Charcot-Marie-Tooth Research Foundation
- Inherited Neuropathy Consortium
- Rare Disease registries
- NIH research grants
- Foundation funding
- Industry partnerships
KARS1 (Lysyl-tRNA Synthetase 1) is an essential enzyme for protein synthesis with critical roles in both cytoplasmic and mitochondrial translation. Its involvement in multiple neurodegenerative diseases, particularly Charcot-Marie-Tooth disease and hereditary spastic paraplegia, highlights its importance for neuronal health. The dual functionality of KARS1 as both a translation factor and signaling molecule makes it a fascinating target for understanding disease mechanisms and developing therapeutics. As research advances, KARS1 continues to provide insights into the fundamental processes of neuronal function and dysfunction.
- Aminoacyl-tRNA synthetases in human disease
- Human mitochondrial aminoacyl-tRNA synthetases
- KARS1 mutations in hereditary spastic paraplegia
- Mitochondrial translation and KARS
- KARS1 and Charcot-Marie-Tooth disease
- Mitochondrial aaRS and disease
- Neurodevelopmental disorders with KARS1 mutations
- Mitochondrial dysfunction in neurodegenerative disease
- Aminoacyl-tRNA synthetases in neurodegeneration
- KARS1 and CMT disease severity
- Aminoacyl-tRNA synthetase complex
- Cytosolic vs mitochondrial KARS isoforms
- KARS1 missense variants in neuropathy
- tRNA charging in neuronal health
- KARS1 and axonal transport
- Mitochondrial translation machinery
- Neuropathy gene panels and KARS1
- aaRS therapies and drug discovery
- KARS1 structural analysis
- KARS1 in auditory neuropathy
- Aminoacyl-tRNA synthetases in human disease
- Human mitochondrial aminoacyl-tRNA synthetases
- KARS1 mutations in hereditary spastic paraplegia
- Mitochondrial translation and KARS
- KARS1 and Charcot-Marie-Tooth disease
- Mitochondrial aaRS and disease
- Neurodevelopmental disorders with KARS1 mutations
- Mitochondrial dysfunction in neurodegenerative disease
- Aminoacyl-tRNA synthetases in neurodegeneration
- KARS1 and CMT disease severity
- Aminoacyl-tRNA synthetase complex
- Cytosolic vs mitochondrial KARS isoforms
- KARS1 missense variants in neuropathy
- tRNA charging in neuronal health
- KARS1 and axonal transport
- Mitochondrial translation machinery
- Neuropathy gene panels and KARS1
- aaRS therapies and drug discovery
- KARS1 structural analysis
- KARS1 in auditory neuropathy
¶ KARS1 in Alzheimer's and Parkinson's Disease
While primarily known for peripheral neuropathies, KARS1 dysfunction may contribute to AD pathogenesis through multiple mechanisms 18:
Protein Synthesis Decline:
- Global reduction in translation capacity with aging
- Impaired local protein synthesis at synapses
- Reduced capacity for activity-dependent protein synthesis
Connection to tau Pathology:
- Altered translation of tau isoforms
- Effects on tau post-translational modifications
- Potential for aggregation-prone species accumulation
Synaptic Protein Synthesis:
- Reduced AMPA and NMDA receptor subunit synthesis
- Impaired scaffolding protein production
- Disrupted activity-dependent translation
KARS1 function intersects with PD pathogenesis through several pathways 19:
tRNA Modifications:
- Post-transcriptional tRNA modifications affect translation fidelity
- Modified tRNAs in PD brains
- Implications for α-synuclein synthesis
Mitochondrial Translation:
- Complex I defects in PDsubstantia nigra
- Role of mitochondrial translation in dopaminergic survival
- Energy failure mechanisms
Axonal Transport:
- Local translation in dopaminergic axons
- Axonal maintenance requirements
- Vulnerability to translation defects
¶ Editing Function and Disease
The editing domain of KARS1 prevents misaminoacylation 10:
- Pre-transfer editing: Hydrolysis of misactivated amino acid-AMP
- Post-transfer editing: Cleavage of incorrectly charged tRNA
- Quality control: Maintains translational fidelity
- Editing domain mutations cause CMT
- Reduced editing leads to toxic misfolded proteins
- Mislocalized amino acids cause cellular stress
KARS1 functions within the multisynthetase complex (MSC) 11:
| Component |
Function |
| KARS1 |
Lysyl-tRNA synthesis |
| EARS |
Glutamyl-tRNA synthesis |
| RARS |
Arginyl-tRNA synthesis |
| AIMP1 |
Scaffold protein |
| AIMP2 |
Scaffold protein |
- Efficient tRNA aminoacylation
- Channeling of charged tRNAs to ribosomes
- Coordinated regulation of translation
KARS1 has cytokine-like functions when secreted 12:
- Extracellular KARS1 activates immune cells
- Cytokine-like signaling
- Wound healing functions
- Released from damaged neurons
- Microglial activation
- Chronic neuroinflammation in neurodegeneration
KARS1's role in axonal translation is critical for neuronal function 13, 14:
- Axonal growth: New protein synthesis for elongation
- Synapse formation: Presynaptic protein synthesis
- Regeneration: Injury response protein synthesis
- Maintenance: Ongoing cytoskeletal protein turnover
- mTOR-dependent regulation
- Activity-dependent translation
- Stress granule formation
- Integrated stress response
Multiple strategies are being developed for aaRS-related disorders 15:
- AAV-mediated KARS1 delivery
- CRISPR-based gene correction
-onsense suppression therapy 16
- Enzyme activators
- Translation fidelity modulators
- Mitochondrial function enhancers
- CoQ10 supplementation
- L-carnitine
- Neuroprotective agents
17 KARS1 as a biomarker:
- Blood KARS1 levels
- CSF analysis
- Disease progression markers
- Aminoacyl-tRNA synthetases in human disease (2017)
- Human mitochondrial aminoacyl-tRNA synthetases (2017)
- KARS1 mutations cause hereditary spastic paraplegia (2015)
- Mitochondrial KARS and translation (2011)
- CMT2 and KARS1 mutations (2018)
- Mitochondrial translation defects in disease (2015)
- Neurodevelopmental disorders with aaRS mutations (2020)
- Mitochondrial dysfunction in neurodegeneration (2014)
- Aminoacyl-tRNA synthetases in neurodegeneration (2020)
- Editing domain function in KARS1 (2017)
- Multisynthetase complex in mammals (2015)
- Extracellular functions of aminoacyl-tRNA synthetases (2016)
- Aging and protein synthesis in neurons (2014)
- Axonal protein synthesis in neuronal function (2015)
- Therapeutic approaches for aaRS disorders (2020)
- Hammerhead ribozyme therapy for KARS1 (2021)
- Aminoacyl-tRNA synthetases in Alzheimer's disease (2020)
- tRNA modifications in Parkinson's disease (2020)
- CRISPR approaches for aaRS diseases (2021)
- Biomarkers for aaRS-related disorders (2021)